{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:11:07Z","timestamp":1793880667076,"version":"4.7.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Role and mechanism of POXC1 regulating PRAME to promote invasion and migration of breast cancer cells","award":["S2021-YF-YBSF-0426  POXC1"],"award-info":[{"award-number":["S2021-YF-YBSF-0426  POXC1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>MET exon 14 skipping is one of the rare mutations in non-small cell lung cancer (NSCLC), involving its pathogenesis and progression. The performances of several MET inhibitors in clinical trials have been validated based on NGS, immunohistochemistry (IHC), and gene copy number assessments. Thus, a detailed understanding of the relationship between these markers and prognosis is required.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study has recruited patients (n\u2009=\u200917) with MET exon 14 skipping mutation and initially screened genes (n\u2009=\u200910) by polymerase chain reaction (PCR) from 257 specimens of NSCLC, including small biopsies and surgical resection. Further, the IHC analysis detected MET overexpression and recorded the score using the MetMAb trial (rial ( recruited patients (n\u2009=\u200917) with MET exstainings). Finally, the fluorescence in situ hybridization (FISH) resulted in the MET amplification with a MET copy number initially screened genes (n\u2009=\u200910) by p.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>PCR results indicated strong MET staining ( 3+) in more than 50% of tumor cells. Among the recruited 17 cases of MET exon 14 skipping, 9 cases presented MET amplification, and 10 cases with MET overexpression. These attributes were not correlated to the clinicopathological characteristics and overall survival. In addition, 4 cases showed gene amplification, and 3 cases presented polyploidy condition. The correlation analysis showed a significant relationship between MET amplification and MET overexpression (Pearson\u2019s r2\u2009=\u20090.4657, P\u2009&lt;\u20090.005).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Together, these findings indicated a significant correlation between MET overexpression and MET amplification in NSCLC patients but no correlation to prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02482-9","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T13:02:20Z","timestamp":1688389340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification"],"prefix":"10.1186","volume":"23","author":[{"given":"Caixia","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"2482_CR1","doi-asserted-by":"crossref","unstructured":"Wei Yin M, Guo Z, Tang et al. MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain\/Amplification and Is a Poor Predictor of Patient Outcome. Cancers (Basel).2022 May 14;14(10):2433.","DOI":"10.3390\/cancers14102433"},{"key":"2482_CR2","unstructured":"NCCN Clinical Practice. Guidelines in Oncology (NCCN Guidelines\u00ae)Non-Small Cell Lung Cancer Version 6.2020."},{"key":"2482_CR3","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2147\/OTT.S231257","volume":"13","author":"H Liang","year":"2020","unstructured":"Liang H, Wang MMET. Oncogene in Non-Small Cell Lung Cancer: mechanism of MET Dysregulation and Agents targeting the HGF\/c-Met Axis. Onco Targets Ther. 2020;13:2491\u2013510.","journal-title":"Onco Targets Ther"},{"key":"2482_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","volume":"18","author":"PM Comoglio","year":"2018","unstructured":"Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18:341\u201358.","journal-title":"Nat Rev Cancer"},{"key":"2482_CR5","doi-asserted-by":"crossref","unstructured":"Fatemeh Moosavi E, Giovannetti L, Saso, et al. HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci. 2019 Dec;56(8):533\u201366.","DOI":"10.1080\/10408363.2019.1653821"},{"key":"2482_CR6","unstructured":"Toshio F. Kenichi Suda,Tetsuya Mitsudomi.Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and future challenges, Lung Cancer: Targets and Therapy, Lung Cancer: Targets and Therapy 2021:1235\u201350."},{"key":"2482_CR7","doi-asserted-by":"crossref","unstructured":"Kurtis D, Davies A, Lomboy, Carolyn A, Lawrence, et al. DNA-Based versus RNA-Based detection of MET exon 14 skipping events in Lung Cancer. J Thorac Oncol. 2019 Apr;14(4):737\u201341.","DOI":"10.1016\/j.jtho.2018.12.020"},{"issue":"2","key":"2482_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1158\/1078-0432.CCR-19-1667","volume":"26","author":"M Victoria","year":"2020","unstructured":"Victoria M, Raymond RB, Lanman, Frederic J, Kaye, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive Lung Cancer. Clin Cancer Res. 2020;26(2):439\u201349.","journal-title":"Clin Cancer Res"},{"key":"2482_CR9","doi-asserted-by":"crossref","unstructured":"Parneet K, Cheema,Shantanu O, Banerji,Normand, Blais et al. Canadian Consensus Recommendations on the management of MET-Altered NSCLC, Curr Oncol. 2021 Nov 9;28(6):4552\u201376.","DOI":"10.3390\/curroncol28060386"},{"key":"2482_CR10","doi-asserted-by":"crossref","unstructured":"Ionescu DN, Stockley TL, Banerji S et al. Consensus Recommendations to optimize testing for new targetable alterations in Non-Small Cell Lung Cancer. Curr Oncol 2022 Jul 15;29(7):4981\u201397.","DOI":"10.3390\/curroncol29070396"},{"key":"2482_CR11","doi-asserted-by":"crossref","unstructured":"Toshio Fujino K, Suda T, Mitsudomi. Lung Cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and Future Challenges, Lung Cancer (Auckl). 2021 May 20;12:35\u201350.","DOI":"10.2147\/LCTT.S269307"},{"key":"2482_CR12","doi-asserted-by":"crossref","unstructured":"Casadevall D, Gimeno J, Clav\u00e9 S, et al. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget. 2015 Jun;30(18):16215\u201326.","DOI":"10.18632\/oncotarget.3976"},{"issue":"7","key":"2482_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.7150\/ijms.34739","volume":"16","author":"FZ Marino","year":"2019","unstructured":"Marino FZ, Bianco R, Accardo M, et al. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int J Med Sci. 2019;16(7):981\u20139.","journal-title":"Int J Med Sci"},{"key":"2482_CR14","doi-asserted-by":"crossref","unstructured":"Melinda A, Pruis, Jan H, von der Th\u00fcsen. Hendrikus Jan Dubbink, MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer? Ann Transl Med. 2020 Nov;8(22):1538.","DOI":"10.21037\/atm-20-3763"},{"key":"2482_CR15","doi-asserted-by":"crossref","unstructured":"Liu X-W, Chen X-R, Rong Y-M, et al. MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: a multi-center study. Transl Oncol. 2020 Dec;13(12):100868.","DOI":"10.1016\/j.tranon.2020.100868"},{"key":"2482_CR16","unstructured":"Gillianne GY, Lai TH, Lim J, Lim et al. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor\u2013mutant non\u2013small-cell Lung Cancer, J Clin Oncol, January 24, 2019."},{"key":"2482_CR17","doi-asserted-by":"crossref","unstructured":"Choi W, Park SY, Lee Y et al. The clinical impact of Capmatinib in the treatment of Advanced Non-Small Cell Lung Cancer with MET exon 14 skipping mutation or gene Amplification.Cancer res treat. 2021 Oct;53(4):1024\u201332.","DOI":"10.4143\/crt.2020.1331"},{"key":"2482_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, J\u00e4nne PA, Verma S, et al. MET exon 14 mutations in Non-Small-Cell Lung Cancer are Associated with Advanced Age and Stage-Dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721\u201330.","journal-title":"J Clin Oncol"},{"key":"2482_CR19","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","volume":"11","author":"AB Schrock","year":"2016","unstructured":"Schrock AB, Frampton GM, Suh J, Chalmers ZR, et al. Characterization of 298 patients with Lung Cancer Harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11:1493\u2013502.","journal-title":"J Thorac Oncol"},{"key":"2482_CR20","doi-asserted-by":"crossref","unstructured":"Daniel Lu A, Nagelberg, Justine LM, Chow et al. MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumorigenesis, Cancers 2022, 14, 1378.","DOI":"10.3390\/cancers14061378"},{"key":"2482_CR21","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-206","volume":"22","author":"JH Tong","year":"2016","unstructured":"Tong JH, Yeung SF, Chan AWH, Lau YC, Shuk LC, Raymond WM, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non- small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22:3048\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-206.","journal-title":"Clin Cancer Res"},{"key":"2482_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","volume":"123","author":"HG Vuong","year":"2018","unstructured":"Vuong HG, Ho ATN, Altibi AMA, Tadao NA, Ryohei KA, Tetsuo KO. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis. Lung Cancer. 2018;123:76\u201382.","journal-title":"Lung Cancer"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02482-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02482-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02482-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T13:03:59Z","timestamp":1688389439000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02482-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2482"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02482-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"14 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Authors reporting experiments on humans and\/or the use of human tissue samples confirm that all experiments were performed in accordance with relevant guidelines and regulations. This study was approved by the Research Ethics Committee at the Shaanxi Cancer Hospital. Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"240"}}